| scholarly article | Q13442814 |
| P50 | author | Bradley M Haverkos | Q87988147 |
| P2093 | author name string | Carrie B Coleman | |
| James P Dugan | |||
| P2860 | cites work | Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus | Q24524755 |
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions | Q24614360 | ||
| The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes | Q24634928 | ||
| The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB | Q24646694 | ||
| Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed | Q25257225 | ||
| Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma | Q39865449 | ||
| Epstein-Barr virus BART gene expression. | Q39895821 | ||
| Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells | Q39969592 | ||
| Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. | Q50888098 | ||
| Complete and durable responses in Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab and Dexamethasone. | Q52597962 | ||
| Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. | Q53109465 | ||
| Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. | Q55518172 | ||
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Q67518698 | ||
| Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy | Q70611076 | ||
| Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon, France, 17-24 June 1997 | Q77096650 | ||
| Keeping it quiet: chromatin control of gammaherpesvirus latency | Q26865827 | ||
| PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model | Q27313748 | ||
| An animal model for acute and persistent Epstein-Barr virus infection | Q28241858 | ||
| Identification of virus-encoded microRNAs | Q28259309 | ||
| Epstein-Barr virus: 40 years on | Q29617969 | ||
| Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases | Q30244110 | ||
| Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas | Q30275251 | ||
| Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma | Q30276132 | ||
| The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment | Q30278553 | ||
| A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies | Q30496656 | ||
| Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters | Q33422971 | ||
| Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle | Q33474804 | ||
| Lymphoid hyperplasia and lymphoma in transgenic mice expressing the small non-coding RNA, EBER1 of Epstein-Barr virus | Q33531732 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Micro RNAs of Epstein-Barr Virus Promote Cell Cycle Progression and Prevent Apoptosis of Primary Human B Cells | Q33680515 | ||
| Epigenetic regulation of EBV persistence and oncogenesis | Q33723664 | ||
| Chromatin organization of gammaherpesvirus latent genomes | Q33729584 | ||
| Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo | Q33755168 | ||
| DNA methylation and the Epstein-Barr virus | Q33765683 | ||
| Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression | Q33783532 | ||
| Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting | Q33789613 | ||
| Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases | Q33793163 | ||
| EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3 | Q33793531 | ||
| Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation | Q33842581 | ||
| Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? | Q33922904 | ||
| Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells | Q33929593 | ||
| Epstein-Barr virus infection | Q34004958 | ||
| Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer | Q34261764 | ||
| The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination | Q34277034 | ||
| Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. | Q34294106 | ||
| Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes | Q34299744 | ||
| The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter | Q34355226 | ||
| BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression | Q34411841 | ||
| Epstein-Barr virus-associated lymphoproliferative disorders. | Q34654750 | ||
| Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells | Q40040836 | ||
| Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes | Q40048949 | ||
| Epstein-Barr Virus LMP1 Mediated Oncogenicity. | Q40073030 | ||
| Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter | Q40075775 | ||
| Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. | Q40330606 | ||
| PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. | Q40336693 | ||
| The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome | Q40516561 | ||
| The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. | Q40526858 | ||
| Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA | Q40617465 | ||
| The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell | Q40843575 | ||
| Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. | Q40950664 | ||
| Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production | Q40951743 | ||
| Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma | Q41033885 | ||
| CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease | Q41158549 | ||
| The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. | Q41371042 | ||
| EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA. | Q41464136 | ||
| Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death | Q41678654 | ||
| The intersection of Epstein-Barr virus with the germinal center | Q41983676 | ||
| Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma | Q42145376 | ||
| The latent membrane protein 1 of Epstein-Barr virus and loss of the INK4a locus: paradoxes resolve to cooperation in carcinogenesis in vivo | Q43481197 | ||
| Azothymidine and interferon-alpha are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma | Q43709652 | ||
| Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. | Q43931328 | ||
| The EBNA-3 gene family proteins disrupt the G2/M checkpoint | Q44036145 | ||
| Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration | Q44142809 | ||
| Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. | Q44342298 | ||
| Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation | Q44618759 | ||
| Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. | Q44790655 | ||
| Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease | Q44983123 | ||
| Viral microRNA profile in Epstein-Barr virus-associated peripheral T cell lymphoma. | Q45394807 | ||
| Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma | Q45722302 | ||
| Global and non‐random CpG‐island methylation in gastric carcinoma associated with Epstein‐Barr virus | Q45723898 | ||
| Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. | Q45758095 | ||
| Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation | Q45780110 | ||
| Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus | Q45802693 | ||
| Effects of n-Butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation | Q45807559 | ||
| Observations on childhood infections with the Epstein-Barr virus | Q45822712 | ||
| Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion | Q45837679 | ||
| The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B | Q45876441 | ||
| Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. | Q34981036 | ||
| An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking | Q35000168 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines. | Q35171856 | ||
| bZIP proteins of human gammaherpesviruses. | Q35179637 | ||
| Epstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. | Q35539925 | ||
| Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma | Q35634894 | ||
| Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion | Q35652539 | ||
| Persistence of the Epstein-Barr virus and the origins of associated lymphomas | Q35715171 | ||
| Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents | Q35733719 | ||
| Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. | Q35787708 | ||
| Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma | Q35788760 | ||
| CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA. | Q35808625 | ||
| Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy | Q35875897 | ||
| The role of miRNAs and EBV BARTs in NPC. | Q35924359 | ||
| Epstein-Barr virus oncoprotein super-enhancers control B cell growth | Q35963272 | ||
| Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer | Q36059593 | ||
| Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma | Q36065290 | ||
| Epigenetic silencing of tumor suppressor genes during in vitro Epstein-Barr virus infection. | Q36079181 | ||
| Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells | Q36135900 | ||
| Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice | Q36327458 | ||
| Noncoding RNA-guided recruitment of transcription factors: A prevalent but undocumented mechanism? | Q36487117 | ||
| EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression | Q36508964 | ||
| Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. | Q36555784 | ||
| Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation | Q36575274 | ||
| Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. | Q36637195 | ||
| Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts | Q36696963 | ||
| Viruses, microRNAs, and host interactions | Q36753937 | ||
| Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs | Q36757012 | ||
| Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye | Q36927515 | ||
| Epstein-barr virus and hodgkin lymphoma | Q37007336 | ||
| Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter | Q37156071 | ||
| Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1. | Q37253033 | ||
| Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. | Q37314721 | ||
| Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers | Q37362803 | ||
| Higher methylation intensity induced by EBV LMP1 via NF-κB/DNMT3b signaling contributes to silencing of PTEN gene | Q37457770 | ||
| Epigenetic regulation of latent Epstein-Barr virus promoters | Q37620765 | ||
| Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes | Q37707304 | ||
| EBNA1 and host factors in Epstein-Barr virus latent DNA replication | Q38049001 | ||
| Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells | Q38322174 | ||
| The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells | Q38597236 | ||
| Core binding factor (CBF) is required for Epstein-Barr virus EBNA3 proteins to regulate target gene expression | Q38728190 | ||
| Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study | Q38892982 | ||
| Burkitt's lymphoma: a review of the pathology, immunology, and possible etiologic factors. | Q38896057 | ||
| A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. | Q38965273 | ||
| Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions | Q38966100 | ||
| Epstein-Barr virus-encoded small non-coding RNAs induce cancer cell chemoresistance and migration | Q39136769 | ||
| Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells | Q39392105 | ||
| The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. | Q39551287 | ||
| Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication | Q39582265 | ||
| Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription | Q39594681 | ||
| Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. | Q39596964 | ||
| Variant chromatin structure of the oriP region of Epstein-Barr virus and regulation of EBER1 expression by upstream sequences and oriP. | Q39603362 | ||
| The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma | Q39606643 | ||
| The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production | Q39735571 | ||
| Nucleosome assembly proteins bind to Epstein-Barr virus nuclear antigen 1 and affect its functions in DNA replication and transcriptional activation | Q39804470 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphoproliferative disorders | Q4165484 |
| Epstein–Barr virus | Q6900 | ||
| P304 | page(s) | 127 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders | |
| P478 | volume | 9 |
Search more.